Clover to supply over 400m COVID-19 vaccine doses to COVAX


Clover Biopharmaceuticals has signed an agreement with Gavi – the vaccine alliance, to make over 400 million doses of its COVID-19 vaccines available to the COVAX portfolio.

Clover through the agreement signed with COVAX co-lead, Gavi, will make over 400 million doses of its vaccine candidate available for procurement in 2021 and 2022, pending Emergency Use Listing from the World Health Organisation.

Clover became the ninth COVID-19 vaccine developer to partner with the Coalition for Epidemic Preparedness Innovations in Spring, 2020, after submitting a proposal to CEPI’s COVID-19 vaccine call launched earlier in the year.

Disclosing this on its website, CEPI said an initial 64 million doses of this vaccine are expected to be available by the end of 2021.

“CEPI’s decision to invest in any COVID-19 vaccine candidate is based on scientific promise, and our core criteria of speed, scale, and access.

“We also worked to build a portfolio that is deliberately diverse, composed of different types of vaccine candidate—from mRNA and DNA vaccines to protein-based vaccines like that developed by Clover,” CEPI said.

CEPI noted that the new agreement between COVAX and Clover will further support low-income and middle-income countries so that they can protect the most vulnerable members of their societies against COVID-19.

“Subject to receiving EUL, Clover’s vaccine will be made available as a two-vial, two-dose programme. Mixing of the two vials (one including the drug substance and another including the adjuvant) will occur at vaccination sites, ahead of administration, as occurs for other vaccines.

“All the vials being used by Clover have been secured through a partnership between CEPI and the Italian-based Stevanato Group, and can each hold up to 20 doses of COVID-19 vaccine.

“Anticipating that the supply of glass vials would become limited, CEPI secured enough vials, back in June 2020, to store 2 billion doses of vaccines and has made these available to its vaccine-development partners,” CEPI noted.

Explaining further, the Director of Vaccine Research and Development, CEPI, Melanie Saville said, “We knew from the outset of the fast-spreading outbreak that we needed a diverse portfolio if we were to have the maximal chance of getting vaccines to licensure.

“Clover ticked all the right boxes and its protein-based vaccine became an important addition within CEPI’s COVID-19 toolbox. It was also an important project where we could not only provide funding and expertise but also access to additional resources, through our other vaccine partnerships, to expedite the development process”.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *